Full Press Release Details
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003.
IMMP
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
Key Takeaway: Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
Price reaction · baseline $3.43 (2021-11-30 close) · hit after-hours · 1 other IMMP headline(s) in the window, move may be shared
day 0 close
-5.8%
day 1
-2%
day 3 · peak
-9.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)